Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation
Por:
Segovia-Mendoza, Mariana, Romero-Garcia, Susana, Lemini, Cristina, Prado-Garcia, Heriberto
Publicada:
7 ene 2021
Resumen:
Breast cancer is the most common neoplasm diagnosed in women around the
world. Checkpoint inhibitors, targeting the programmed death receptor-1
or ligand-1 (PD-1/PD-L1) axis, have dramatically changed the outcome of
cancer treatment. These therapies have been recently considered as
alternatives for treatment of breast cancers, in particular those with
the triple-negative phenotype (TNBC). A further understanding of the
regulatory mechanisms of PD-L1 expression is required to increase the
benefit of PD-L1/PD-1 checkpoint immunotherapy in breast cancer
patients. In this review, we will compile the most recent studies
evaluating PD-1/PD-L1 checkpoint inhibitors in breast cancer. We review
factors that determine the therapeutic success of PD-1/PD-L1
immunotherapies in this pathology. In particular, we focus on pathways
that interconnect the epithelial-mesenchymal transition (EMT) with
regulation of PD-L1 expression. We also discuss the relationship between
cellular metabolic pathways and PD-L1 expression that are involved in
the promotion of resistance in TNBC.
Filiaciones:
Univ Nacl Autonoma Mexico, Dept Farmacol, Fac Med, Mexico City 04510, DF, Mexico
Dept Enfermedades Cron Degenerat, Lab Oncoinmunobiol, Ismael Cosio Villegas Calzada Tlalpan 4502, Mexico City 14080, DF, Mexico
|